
NeuBase Therapeutics NBSE
Quarterly report 2023-Q3
added 05-16-2026
NeuBase Therapeutics ROE Ratio 2011-2026 | NBSE
Annual ROE Ratio NeuBase Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23.97 | -16.4 | -55.55 | -260.56 | 100.13 | -104.23 | -103.22 | -14.46 | -16.97 | -38.41 | -91.43 | 106.69 | -129.26 | -141.09 | 74.79 | 2395.74 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2395.74 | -260.56 | 105.11 |
Quarterly ROE Ratio NeuBase Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -102.88 | -110.97 | -106.32 | -94.39 | -86.81 | -73.17 | -70.23 | -68.1 | -65.96 | -62.54 | -149.23 | -199.08 | -248.92 | -252.24 | -155.17 | -99.97 | 343.37 | 354.47 | 354.78 | 342.6 | -57.73 | -68.5 | -97.42 | -103.32 | -109.23 | -121.81 | -95.38 | -84.19 | -73.0 | -53.81 | -46.02 | -50.55 | -54.83 | -54.62 | -106.71 | -132.97 | -159.49 | -172.61 | -126.28 | -490.31 | -854.35 | -1094.36 | -878.03 | -477.55 | -77.08 | 271.97 | 134.07 | 136.89 | 88.78 | 65.62 | -7.33 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 354.78 | -1094.36 | -107.86 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-32.54 | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
21.0 | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
30.52 | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
3750.6 | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
-55.98 | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
7.51 | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
-17.59 | $ 32.59 | -6.89 % | $ 877 M | ||
|
Forte Biosciences
FBRX
|
-113.75 | $ 21.59 | -1.86 % | $ 280 M | ||
|
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
-948.23 | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | ||
|
IMV
IMV
|
575.45 | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
-5.91 | $ 92.14 | 1.33 % | $ 22.3 B | ||
|
Grifols, S.A.
GRFS
|
2.47 | $ 7.98 | -1.6 % | $ 5.42 B | ||
|
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.7 | 3.03 % | $ 452 M | ||
|
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
-139.54 | $ 0.86 | -1.42 % | $ 143 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
43.82 | - | -4.36 % | $ 27 M | ||
|
Compugen Ltd.
CGEN
|
34.4 | $ 2.8 | 7.28 % | $ 262 M | ||
|
Anika Therapeutics
ANIK
|
-7.58 | $ 14.88 | -0.93 % | $ 213 M | ||
|
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | ||
|
Incyte Corporation
INCY
|
24.9 | $ 97.16 | -0.26 % | $ 19 B | ||
|
Ionis Pharmaceuticals
IONS
|
-46.9 | $ 75.56 | -0.29 % | $ 12.1 B | ||
|
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.4 | -1.16 % | $ 5.6 M | ||
|
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
275.39 | $ 1.61 | 2.55 % | $ 189 M | ||
|
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-146.95 | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 20.86 | -0.71 % | $ 2.65 B | ||
|
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M |